Novigenix awarded EUR 1.8M in the groundbreaking BRECISE IHI Consortium to industrialize AI-powered liquid biopsy for prediction of immunotherapy response
Lausanne, Switzerland, March 31, 2025 – Novigenix, a leader in AI-driven precision liquid biopsy solutions, has been awarded EUR 1.8M through the new BRECISE IHI grant funded by the European Union (EU) research initiative focusing on revolutionizing cancer diagnostics, treatment, and monitoring through advanced multi-omics and artificial intelligence. The BRECISE consortium was launched last